Abstract:BackgroundPARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in BRCA1/2 are notably rare in pancreatic cancer.ObjectiveThere is a significant unmet clinical need to broaden the utility of PARPi.DesignRNA sequencing was performed to screen potential targets for PARPi sensitivity. The synthetic lethal effects were verified in patient-derived xenograft (PDX), xenograft and patient-derived organoid models. Mechanisms were explored via LC‒MS/MS, coimmunoprecipitation, laser microirradiation, immunofluorescence, the homologous recombination (HR) or non-homologous end joining (NHEJ) reporter system, in situ proximity ligation assay and live-cell time-lapse imaging analyses.ResultsTargeting protein for Xenopus kinesin-like protein 2 (TPX2) is an exploitable vulnerability. TPX2 was downregulated in PDX models sensitive to PARPi, and TPX2 inhibition conferred synthetic lethality to PARPi bothin vitroandin vivo. Mechanistically, TPX2 functions in a cell cycle-dependent manner. In the S/G2 phase, ATM-mediated TPX2 S634 phosphorylation promotes BRCA1 recruitment to double-strand breaks (DSBs) for HR repair, whereas non-phosphorylated TPX2 interacts with 53BP1 to recruit it for NHEJ. The balance between phosphorylated and non-phosphorylated TPX2 determines the DSB repair pathway choice. During mitosis, TPX2 phosphorylation enhances Aurora A activity, promoting mitotic progression and chromosomal stability. Targeting TPX2 S634 phosphorylation with a cell-penetrating peptide causes genomic instability and mitotic catastrophe and enhances PARPi sensitivity. Additionally, the inhibition of TPX2 or S634 phosphorylation combined with gemcitabine further sensitised pancreatic cancer to PARPi.ConclusionsOur findings revealed the dual-functional significance of TPX2 in controlling DNA DSB repair pathway choice and mitotic progression, suggesting a potential therapeutic strategy involving PARPi for patients with pancreatic cancer.

Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Inactive PARP1 causes embryonic lethality and genome instability in a dominant-negative manner

Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability

Poly(ADP-Ribose) Polymerase-1 Lacking Enzymatic Activity Is Not Compatible with Mouse Development

Molecular Basis of XRN2-Deficient Cancer Cell Sensitivity to Poly(ADP-ribose) Polymerase Inhibition

Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

TPX2 Serves As a Novel Target for Expanding the Utility of PARPi in Pancreatic Cancer Through Conferring Synthetic Lethality

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

Transcription–replication conflicts underlie sensitivity to PARP inhibitors

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment

PARP is important for genomic stability but dispensable in apoptosis

PARG inhibition induces nuclear aggregation of PARylated PARP1

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition

Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA -proficient cancer cells to PARP inhibitors

BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality

C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption

The complex universe of inactive PARP1